Argos is focused on the treatment of metastatic cancers and chronic infections using a proprietary platform technology that stimulates immune cells with messenger RNA. The company’s lead product is for the personalized treatment of advanced renal cell carcinoma and is in phase III clinical development. A second product for therapeutic vaccination in HIV is in phase II development. Argos has also developed an interferon-neutralizing antibody for systemic lupus and has developed a CD83 Soluble Protein for Transplant Rejection/ Autoimmune Disorders in late preclinical development. Argos is listed on Nasdaq and traded under the symbol ARGS.
Total raised: $171M
Founder name: Jeff Abbey

Investors 2

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
20.11.2013Series E$17.5M-Argos Ther...
26.08.2013Series E$42.5M-Argos Ther...
24.04.2012Series D$25M-Argos Ther...
29.07.2011IPO$86M-What Argos...

Mentions in press and media 12

DateTitleDescriptionCategoryAuthorSource
29.06.2016The biotec...There was a time af­ter the 2...FinancingJohn Carro...endpts.com...
20.11.2013Argos Ther...Argos Therapeutics Inc., a Dur...Uncategori...-finsmes.co...
28.08.2013Argos Ther...Argos Therapeutics Inc., a Dur...funding U...-finsmes.co...
15.01.2013Personaliz...CEO Jeff Abbey told MedCity Ne...--medcitynew...
08.06.2012Experiment...Argos had planned to support i...--medcitynew...
24.04.2012Argos rais...Full phase 2 results of AGS-00...--medcitynew...
24.04.2012Argos Ther...Argos Therapeutics, a Durham, ...funding U...-finsmes.co...
07.03.2012No IPO for...But the public markets have re...--medcitynew...
29.07.2011Argos Ther...Argos’ immunotherapy technol...--medcitynew...
29.07.2011What Argos...Proceeds from the stock offeri...--medcitynew...
Show more